protocolSection identificationModule nctId: NCT06387511, orgStudyIdInfo id: NutriVax-Measles, briefTitle: Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-06-15, completionDateStruct date: 2025-06-15, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Alliance for International Medical Action, class: OTHER, collaborators name: Institut National de la Santé Et de la Recherche Médicale, France, collaborators name: Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire, collaborators name: Yobe State Ministry of Health, Nigeria, collaborators name: Eleanor Crook Foundation, collaborators name: Gavi, The Vaccine Alliance, descriptionModule briefSummary: Provision of SQ-LNS also holds promise in incentivizing vaccination as well as other health services.We will estimate 1) the effectiveness of a SQ-LNS mass supplementation program added to routine immunization program compared to routine immunization program alone in terms of measles vaccine coverage, after 12 months of program implementation, 1) in children aged 12-23 months in the endline cross-sectional household survey, 2) in children aged 6-12 months at inclusion in a longitudinal 12 months follow-up survey.Secondary objectives are to assess the barriers and facilitators from the perspectives of parents/legal guardian of children, health care providers and community health workers and to assess the cost-efficiency of theThis study will implrmented in 20 wards covering the Karasuwa and Nguru Local Government Areas (LGAs) in Yobe state, Northeast Nigeria.This is a pragmatic parallel cluster randomized trial (PCT) with baseline measure with different populations and data collection modes: 1) baseline and endline cross-sectional household surveys of children aged 12-23 months, 2) a longitudinal follow-up survey (LS) of children aged 6-12 months at inclusion, 3) a qualitative feasibility and acceptability survey of parents of children aged 6-23 months, of health providers, of community health workers and community representatives and 4) a cost survey of parents/legal guardian of children from the longitudinal follow-up cohort, and 5) a health facility cost survey of a randomized sub-sample of health facilities.Clusters will be randomly allocated at a ratio of 1:1 either to the standard arm or to the NutriVax arm:* The standard Expanded Program on Immunization (EPI) in children aged 6-23 months delivered according to the Ministry of Health's routine plans in the community and at health centres and health posts, named the standard EPI arm;* The NutriVax program combining the EPI in children aged 6-23 months according to the Ministry of Health's routine plans in the community and at health centres (i.e. PHCCs) and health posts associated with SQ-LNS mass supplementation integrated into pre-existing services delivered at health centres (i.e. PHCCs) for children 6-23 months of age, named the NutriVax arm., conditionsModule conditions: Immunization Coverage Improvment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A two arms opened pragmatic parallel cluster-randomized controlled trial with baseline measure, primaryPurpose: PREVENTION, maskingInfo masking: NONE, maskingDescription: No possible to mask intervention due to the specifity of the intervention tested, enrollmentInfo count: 3720, type: ESTIMATED, armsInterventionsModule interventions name: Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax, outcomesModule primaryOutcomes measure: Measles vaccine coverage in children aged 12-23 months, primaryOutcomes measure: Measles vaccine coverage in children 6-12 months at inclusion, secondaryOutcomes measure: Measles vaccine coverage: at least one dose, secondaryOutcomes measure: Measles vaccine coverage : two doses, secondaryOutcomes measure: Timeliness of measles 1 vaccination, secondaryOutcomes measure: Other infant vaccines coverage, secondaryOutcomes measure: Zero-dose, secondaryOutcomes measure: Fully immunization, secondaryOutcomes measure: Acceptability, secondaryOutcomes measure: Cost-efficiency, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 23 Months, stdAges: CHILD, contactsLocationsModule, hasResults: False